Optionale Produktanalyse
Mit Ihrer Erlaubnis verwenden wir datenschutzfreundliche Analysen, um zu verstehen, welche Recherchewege funktionieren. Wir verwenden weder Werbe-Tracker noch Sitzungsaufzeichnungen. Sie können diese Auswahl in den Einstellungen ändern. Lesen Sie die Datenschutzerklärung.
Illinois Tool Works Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $74.9B | |
|---|---|---|
| Revenue (ttm) | 16.6B | |
| Net income (ttm) | 3.2B | |
| EPS (ttm) | $11.2 | |
| Shares out | 284.8M | |
| P/E (trailing) | 24.7x | |
| P/E (forward) | 21.9x | |
| Dividend | $6.88 (2.50%) | |
| Volume | 971,173 | |
| Beta | 0.97 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $14.46B | $15.93B | $16.11B | $15.90B | $16.04B | +2.6% |
| Gross profit | $5.97B | $6.50B | $6.79B | $6.94B | $7.08B | +4.4% |
| Operating income | $3.48B | $3.79B | $4.04B | $4.26B | $4.22B | +4.9% |
| Net income | $2.69B | $3.03B | $2.96B | $3.49B | $3.07B | +3.3% |
| EPS (diluted) | $8.51 | $9.77 | $9.74 | $11.71 | $10.49 | +5.4% |
| EBITDA | $3.66B | $4.18B | $4.04B | $5.11B | $4.65B | +6.2% |
| R&D | $239.0M | $269.0M | $284.0M | $292.0M | $302.0M | +6.0% |
| SG&A | $2.36B | $2.58B | $2.62B | $2.68B | $2.78B | +4.2% |
Recent company headlines from major financial publishers.
Under the base path, ITW delivers disciplined operational execution across operating segments. Free cash flow conversion exceeds guided benchmarks, supporting dividend compounding and regular share repurchases. Discounted at the house cost of equity with normalized terminal valuation multiples, this yields the central Fair value of $195.02.
Global industrial demand accelerates across North America, EMEA, and Asia Pacific. Accelerated adoption of Customer-Back Innovation products expands market share while operational cell efficiencies deliver strong incremental margins. Free cash flow conversion exceeds net earnings, funding accelerated buybacks that expand diluted share compounding and lift intrinsic valuation toward Potential value of $222.75.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 8.3% | $207 | $211 | $215 | $219 | $224 |
| 8.8% | $198 | $201 | $204 | $208 | $212 |
| 9.3% | $190 | $192 | $195 | $198 | $201 |
| 9.8% | $183 | $185 | $187 | $190 | $192 |
| 10.3% | $176 | $178 | $180 | $182 | $184 |
Upcoming earnings date and setup when available.
Das Rating, das die veröffentlichte Research-Ausgabe des jeweiligen Monats trug. Ein Rating vergleicht den Kurs zum Analysezeitpunkt mit dem Fair Value; es ist kein Nachweis, ob die Einschätzung zutraf.
| Jahr | Jan | Feb | Mär | Apr | Mai | Jun | Jul | Aug | Sep | Okt | Nov | Dez |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |